Epimune’s goal is to revolutionize diagnosis and monitoring of patients with disorders of the immune system
Using epigenetics, Epimune develops & commercializes molecular diagnostic tests for immune cell quantification from a drop of blood
Berlin, 16 October 2020 - Epimune today completed CE-marking of its i.Mune TBNK Test for use with Dried Blood Spot (DBS) samples.
In addition to the already available quantification of T-, B- and NK lymphocytes from as little as 40 µl of fresh venous whole blood, DBS-based testing now enables applications where a fresh blood sample is difficult or impossible to obtain. This includes lymphocyte profiling in infants, patient management in remote areas with limited infrastructure for fresh blood sample transport or self-sampling of home-bound individuals.
For a Spanish version of this video please click here!